Recon: US pulls funding for Inovio COVID vaccine study; EU seeks 1.8 billion more doses of Pfizer-BioNTech vaccine

• With Few New Clotting Cases, J&J Pause Could Be Lifted Soon (NYTimes) (WSJ) (Reuters) (FT)
• White House writes off Johnson & Johnson vaccine after string of production failures (Politico)
• US CDC probes new death, hospitalization after J&J vaccine shots – officials (Reuters)
• US stops funding for late-stage study of Inovio's COVID-19 vaccine (Reuters) (Endpoints)
• CDC reassigns official who drew spotlight for pandemic warning (Politico)
• New data point to benefits of Bristol’s novel psoriasis pill, but safety issues will be scrutinized (STAT)
• FDA Authorizes Marketing of Device to Facilitate Muscle Rehabilitation in Stroke Patients (FDA)
• ‘There are no alternatives’: As Pfizer discontinues an old glaucoma drug, a small group of patients struggles to cope (STAT)

• EU to strike world's largest vaccine deal with Pfizer (Reuters)
• EU approves ramp-up of Pfizer vaccine manufacturing site in Belgium (Reuters)
• EU Commission sees potential in protein-based COVID-19 vaccines (Reuters)
• Moderna CEO says world faces 2022 COVID vaccine production surplus (Reuters)
• WHO, Macron denounce vaccine inequity as COVAX scheme marks first year (Reuters)
• India's Cadila Healthcare starts producing COVID-19 vaccine candidate (Reuters)
• MHRA authorises Amarin’s heart drug Vazkepa (PharmaTimes)
• Malaria vaccine trial raises hopes of beating disease (FT)
• Final Opinion On The Safety Of Breast Implants In Relation To ALCL (EC)
• ACT-Accelerator one year on (WHO)

• As At-Home Coronavirus Tests Hit Pharmacies, What Role Can They Play In The Pandemic? (NPR)
• Patients With Long Covid Face Lingering Worrisome Health Risks, Study Finds (NYTimes)
• Vaccines Are Effective Against the New York Variant, Studies Find (NYTimes)
• British regulator says AstraZeneca COVID shot clots rise to 168 (Reuters)
• Brazil's COVID-19 vaccination program at risk due to 2nd dose no-shows (Reuters)
• Norway offers mRNA COVID-19 vaccines to those who first got AstraZeneca's (Reuters)
• Swedish health agency extends pause on J&J vaccine (Reuters)
• Germany sets no limits on use of J&J COVID-19 shot (Reuters)
• Olumiant Snags Japan Approval for COVID-19 (PharmaJapan)
• J&J COVID-19 vaccine expected to be imported to India by July – report (Economic Times)

• J&J shareholders approve CEO Gorsky's near-$30 mln pay plan (Reuters)
• Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance (PharmaPhorum)
• Why GSK will struggle to mount AstraZeneca-style revival (FT)
• With new PhI­II da­ta in hand, Der­ma­vant lines up top­i­cal pso­ri­a­sis con­tender for a sprint to the fin­ish line (Endpoints)
• Regeneron looks to inject another $330M into long-running manufacturing expansion plan: report (Fierce)
• With 7 PD-1s on the mar­ket, price com­pe­ti­tion has­n't been a fac­tor. Will Re­gen­eron be the first to ask for less? (Endpoints)
• Lonza to invest over £150 million on new molecule complex (Pharmafile)
• China Cancer Drug Off-Label Use: A Crossed Line? (Pink Sheet)
• Glax­o­SmithK­line hus­tles the 7th PD-1 past the fin­ish line with Jem­per­li. But how big will up­take be? (Endpoints)
• April show­ers bring more biotechs to Nas­daq, as Rain and Im­pel bump 2021's to­tal raise above $6B (Endpoints)
• Bay­er plots a ma­jor facelift at Berke­ley cam­pus, un­cork­ing a 30-year, $1.2B plan to dri­ve cell and gene ther­a­pies (Endpoints)
• A pair of Bayer execs land promotions in the US; Energized by lenzilumab data, Humanigen taps AstraZeneca alum as CMO (Endpoints)
• The ICH Q3C(R8) Guideline reaches Step 4 of the ICH Process (ICH)
• Pricing Reform in Japan: How Must Life Science Companies Evolve? (PharmaJapan)
• Takeda Teams Up with IT Startup for AI-Driven Early HAE Detection (PharmaJapan)

• Medtech earnings show early signs of electives return, lingering testing uncertainty (MedtechDive)
• Quest Q1 revenue jumps 49% even as COVID-19 test demand wanes (MedtechDive)
• Roche nets companion diagnostic approval for GlaxoSmithKline's Jemperli in MMR-deficient endometrial cancer (Fierce)
• UK Device Regulatory System Off To Good Start Under ‘Supportive’ MHRA (MedtechInsight)
• Endeavour Vision raises $375M to fund post-COVID medtech ambitions (Fierce)
• FDA Presses Domestic Manufacturers To Engage In Remote Regulatory Assessments In Lieu Of Inspections (MedtechInsight)
• Can real-world remote monitoring help doctors treat heart failure? Amgen and Datos aim to find out (Fierce)

• Sen­a­tors to NIH: Do more to pro­tect US bio­med­ical re­search from for­eign in­flu­ence (Endpoints)
• GenMark Sued by Holder Eyeing $1.8 Billion Roche Deal Challenge (Bloomberg)
• How the SCO­TUS de­ci­sion to gut the FTC could help bio­phar­ma com­pa­nies (Endpoints)
• Amgen Petitions Federal Circuit to Reconsider Decision Invalidating Praluent Patents (Big Molecule Watch)